EBV lytic cycle inducer-1

Art. -Nr.: HY-149577 Reinheit: 96.24%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Epstein-Barr virus (EBV) lytic cycle inducer-1 Dp44mT (compound C7) is an iron-chelatoe-like compound. Dp44mT cooperates with HDAC inhibitor Romidespin (HY-15149) and SAHA to induce EBV lytic cycle. Dp44mT reactivates EBV lytic cycle by activating the ERK1/2-autophagy axis in epithelial cancers.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

EBV lytic cycle inducer-1 Chemische Struktur

CAS. Nr. : 394668-43-0

Größe	Verfügbarkeit	Menge
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	Auf Lager	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	Auf Lager	Estimated Time of Arrival: December 31
Solid
5 mg	Auf Lager	Estimated Time of Arrival: December 31
10 mg	Auf Lager	Estimated Time of Arrival: December 31
25 mg	Auf Lager	Estimated Time of Arrival: December 31
50 mg	Auf Lager	Estimated Time of Arrival: December 31
100 mg	Auf Lager	Estimated Time of Arrival: December 31
200 mg	Angebot einholen
500 mg	Angebot einholen

or Massenanfrage

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Spezialitätsempfehlungen

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biologische Aktivität
Reinheit & Dokumentation
Verweise
Kundenbewertung

Beschreibung

In Vitro

Dp44mT (compound C7) (0-80 μM; 48 h) induces lytic cycle in cell line-dependent manner, with higher toxicity in AGS-BX1 than in AGS^[1].
Dp44mT (10 μM; 0-72 h) induces lytic cycle in a time-dependent manner^[1].
Dp44mT (1.25-2.5 μM; 24 h) cooperates with HDAC inhibitor Romidespin and SAHA to induce EBV lytic cycle^[1].
Dp44mT (20 μM; 48 h) leads to the EBV lytic cycle through induction of the ERK-autophagy axis^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[1]

Cell Line:	AGS AGS-BX1
Concentration:	10 μM
Incubation Time:	24 h, 48 h, 72 h
Result:	Resulted the expression of IE proteins Zta, Rta, and early EBV lytic protein BMRF1 peaking at 24h post treatment.

Immunofluorescence^[1]

Cell Line:	AGS-BX1
Concentration:	1.25 μM, 2.5 μM
Incubation Time:	24 h
Result:	Synergistically induced the expression of the viral IE protein Zta could together with 2.5 μM of SAHA and 2.5 nM of Rmidepsin.

Immunofluorescence^[2]

Cell Line:	HA cells
Concentration:	20 μM
Incubation Time:	24 h
Result:	A significantly lower expression of Zta was observed in cells treated with the iron-precomplexed C7 when compared to cells treated with C7 with 41% higher.

Cell Proliferation Assay^[1]

Cell Line:	AGS, AGS-BX1
Concentration:	0 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM, 80 μM
Incubation Time:	48 h
Result:	Displayed significantly higher toxicity to the EBV-positive cell line AGS-BX1 than the EBV-negative counterpart.

Molekulargewicht

318.17

Formel

C₁₄H₁₂BrN₃O

CAS. Nr.

394668-43-0

Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=CC(Br)=CC=C1)N/N=C(C)/C2=NC=CC=C2

Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 12.5 mg/mL (39.29 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.1430 mL	15.7149 mL	31.4297 mL
5 mM	0.6286 mL	3.1430 mL	6.2859 mL
10 mM	0.3143 mL	1.5715 mL	3.1430 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner
Verdünnungsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.56 mg/mL (1.76 mM); Clear solution

This protocol yields a clear solution of ≥ 0.56 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.6 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.56 mg/mL (1.76 mM); Clear solution

This protocol yields a clear solution of ≥ 0.56 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.6 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 0.56 mg/mL (1.76 mM); Clear solution

This protocol yields a clear solution of ≥ 0.56 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.6 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Reinheit & Dokumentation

Purity: 96.25%

Select Batch:

Data Sheet (275 KB) SDS (396 KB)

COA (245 KB) HNMR (134 KB) LCMS (176 KB)

Handling Instructions (2659 KB)

Verweise

[1]. Chung King Choi, et al. Identification of Novel Small Organic Compounds with Diverse Structures for the Induction of Epstein-Barr Virus (EBV) Lytic Cycle in EBV-Positive Epithelial Malignancies. PLoS One. 2015 Dec 30;10(12):e0145994.

[2]. Stephanie Pei Tung Yiu, et al. Intracellular Iron Chelation by a Novel Compound, C7, Reactivates Epstein–Barr Virus (EBV) Lytic Cycle via the ERK-Autophagy Axis in EBV-Positive Epithelial Cancers Cancers 2018 Dec; 10(12): 505.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.1430 mL	15.7149 mL	31.4297 mL	78.5743 mL
	5 mM	0.6286 mL	3.1430 mL	6.2859 mL	15.7149 mL
	10 mM	0.3143 mL	1.5715 mL	3.1430 mL	7.8574 mL
	15 mM	0.2095 mL	1.0477 mL	2.0953 mL	5.2383 mL
	20 mM	0.1571 mL	0.7857 mL	1.5715 mL	3.9287 mL
	25 mM	0.1257 mL	0.6286 mL	1.2572 mL	3.1430 mL
	30 mM	0.1048 mL	0.5238 mL	1.0477 mL	2.6191 mL